Prohost Biotechnology Online

The Newsletter of Biotechnology Research and Investment

   To Subscribe Click

  Subscribe now!!!.

 

  

 

wpe1.jpg (4549 bytes)

P R O H O S T   O n l i n e
The Newsletter of Biotechnology Insight and Investment

 

Eye on the News

[ Home | Contents | Search | Next | Previous | Up ]


ANTISENSE: ISIS, PROMISING RESULTS.

couplesseduceteens x nd13 x

Date: 11 Dec 2007
Time: 18:47:58

Comments

http://www.couplesseduceteens.com/?revid=28792 http://www.cartoon69.com/?revid=28792 http://www.collegewildparties.com/?revid=28792 http://www.dopornstars.com/?revid=28792 http://www.discountrealitysites.com/?revid=28792 http://www.ebonyjoy.com/?revid=28792 http://www.euroteensxxx.com/?revid=28792 http://www.milfhunter.com/?id=chikenn

Date: 18 Jun 2001
Time: 09:21:25

Comments

In a Phase I/II clinical trial, ISIS 14803 demonstrated dose-dependent antiviral activity, decreasing viral titers, or level of virus in blood, in patients with drug resistant chronic Hepatitis C Virus (HCV) on drug resistant forms. All but one patient had failed previous interferon-based therapy.

ISIS 14803 was well tolerated.

Adverse events reported were minor and non-specific.

ALT flares were not accompanied by changes in bilirubin, albumin, or prothrombin time, which are measures of liver synthetic function.

Liver biopsy results obtained during an ALT flare did not show evidence of drug-related liver toxicity.

Antisense is starting to shpow results.

(Refer to Prohost Newsletter, June 2001.)

 




 

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.

Send mail to CompanyWebmaster with questions or comments about this web site.
Copyright © 2001 CompanyLongName
 

 
Send mail to prohost@aol.com with questions or comments about this web site.
Copyright © 2003 Prohost Research, Inc.